Schering-Plough CEO calls takeover prices 'breath-taking'

Share this article:
The prices being paid in the recent rash of pharmaceutical acquisition deals are “breath-taking,” Schering-Plough CEO Fred Hassan said in an interview with Marketwatch.com. “They would have been unthinkable five years ago,” Hassan said. According to Hassan, the takeover craze has been fueled by a recent rash of patent expirations–Merck’s Zocor, Bristol-Myers Squibb’s Pravachol and Pfizer’s Zoloft. “The industry’s R&D engines are struggling to keep up with the expirations,” Hassan said. Hassan said his company doesn’t feel as strong a need to make a major merger or acquisition deal, “as our existing products (patents) go into the next decade.” Hassan also thinks his company can grow with its existing pipeline. Products in development include: *A Phase II blood thinner that could rival or be used in combination with Plavix *The Phase II HIV treatment vicriviroc *A protease inhibitor to treat hepatitis C, currently in Phase II testing * Golimumab, a potential successor to the rheumatoid arthritis drug Remicade, in Phase II testing When asked about rumors suggesting Schering-Plough is eyeing a possible merger with Bristol-Myers Squibb, Hassan declined to comment. “But it’s nice that we’re doing so well that people are talking about us that way,” he said.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Sales

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.